Two-Stage Business Model for Reinvesting Earnings from the Metabolome Analysis Business into the Biomarker Business
First written in FY2017. 2 of 4 entries say "Restated". Latest entry: FY2021.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2021, 2 years before the typical company in this theme (2023).
The whole theme swung hardest in 2023: 2 of 11 companies on the "Worse" side.
5 other companies' latest entry also says "Reframed".
- FY2021ReframedAnnual report
「The Group's medium-term management strategy is to achieve sustainable earnings growth in its core Advanced Research and Development Support Business, including the Metabolomics Business and new contract analysis services through the fiscal year ending June 2021, and to establish its Healthcare Solutions Business at an early stage, including the Biomarker Business and new businesses through the fiscal year ending June 2021.」
The wording changed from the previous two-stage model of investing earnings from the Metabolomics Business in the Biomarker Business to a medium-term management strategy built around two businesses: the Advanced Research and Development Support Business and the Healthcare Solutions Business. - FY2020RestatedAnnual report
「The Group's medium- to long-term management strategy is to secure sufficient short- to medium-term earnings from the Metabolomics Business to cover the company-wide costs required to continue operating the business, while investing the funds generated there ahead of schedule in the Biomarker Business to pursue greater future earnings.」
The Group continues its two-stage business model of making upfront investments in the Biomarker Business using earnings from the Metabolomics Business. - FY2019RestatedAnnual report
「The Group's medium- to long-term management strategy is to secure short- to medium-term earnings from the Metabolomics Business while investing the funds generated there in the Biomarker Business to pursue greater earnings.」
The Group has reaffirmed its two-stage business model of investing earnings from the analysis business in the Biomarker Business. - FY2017First statedAnnual report
「The Group's medium- to long-term management strategy is to secure short- to medium-term earnings from the Metabolome Analysis Business while investing the funds generated there in the Biomarker Business to pursue greater earnings.」
The Group has stated a business model of investing short- to medium-term earnings from the analysis business in the medium- to long-term Biomarker Business.